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Background: Gastroesophageal reﬂux disease (GERD) is a common upper gastrointestinal disease, and
almost 30% of GERD patients do not respond well to proton pump inhibitor (PPI) therapy. The aim of this
study is to evaluate the clinical characteristics of elderly GERD patients who either respond to or resist
PPI therapy.
Methods: A total of 198 patients (75.9 ± 6.4 years, 73.7% males) with GERD receiving PPI treatment were
enrolled in this study. Enrolled patients were requested to complete a questionnaire and a personal
interview concerning their demographics, comorbidities, symptoms, and endoscopic ﬁndings.
Results: Among the 198 enrolled patients, 135 responded to PPI once or twice daily (Group R), while 63
failed to respond to PPI twice daily (Group F). Cross-group differences were detected for body mass index
(p ¼ 0.042), family status (p ¼ 0.028), depression (0.7% vs. 7.9%, p ¼ 0.03), compliance (77% vs. 60%,
p ¼ 0.015), and hiatal hernia (6.7% vs. 17.5%, p ¼ 0.019).
Conclusion: PPI failure appears to be signiﬁcantly inﬂuenced by body mass index, family status,
depression, compliance, and hiatal hernia of GERD patients.
Copyright © 2016, Taiwan Society of Geriatric Emergency & Critical Care Medicine. Published by Elsevier
Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Gastroesophageal reﬂux disease (GERD) is a chronic and com-
mon upper gastrointestinal disease, the incidence of which in Eu-
ropean and American countries is in the range of 10e20%1. Several
studies have demonstrated that over 40% of the US adult population
report GERD-related symptoms at least once a month and 20% once
a week2e4. In China, the prevalence of GERD symptoms is about
9%5. Although not a life-threatening disease, GERD has a signiﬁcant
impact on patients' health and quality of life.
At present, proton pump inhibitors (PPIs) still represent the
cornerstone of treatment for both erosive esophagitis (EE) healing
and symptom relief. However, studies have shown that up to 40% ofre that they have no conﬂicts
f Geriatric Gastroenterology,
g, China.
).
atric Emergency & Critical Care M
censes/by-nc-nd/4.0/).GERD patients reported either partial or complete lack of response
of their symptoms to a standard PPI dose once or twice daily6.
When PPI therapy failed, physicians are often inclined to in-
crease the dose of PPI or change to an alternative for symptomatic
relief. However, this therapeutic strategy frequently results in a less
satisfactory symptomatic relief, and the majority of patients
continue to experience GERD symptoms. To explore the underlying
mechanisms that are accounted for PPI failure, a lot of research has
been carried out and several mechanisms have been proposed,
including lifestyle, adherence to and compliance with treatment,
esophageal hypersensitivity, ultrastructural and functional changes
in the esophageal epithelium, etc6. However, only a few studies
have focused on elderly GERD patients. As a special population,
elderly patients show a lack of typical reﬂux symptoms and are
more likely to suffer from severe diseases and esophagal compli-
cations. Moreover, some available treatments for GERD may be
more dangerous to the elderly patients7. In this study, we compared
the clinical characteristics of elderly GERD patients who failed toedicine. Published by Elsevier Taiwan LLC. This is an open access article under the
Table 1
Los Angeles classiﬁcation of esophagitis.
Grade A One (or more) mucosal break no longer than 5 mm that does
not extend between the tops of two mucosal folds
Grade B One (or more) mucosal break more than 5 mm long that does
not extend between the tops of two mucosal folds
Grade C One (or more) mucosal break that is continuous between the
tops of two or more mucosal folds but involves <75% of the
circumference
Grade D One (or more) mucosal break that involves at least 75% of the
esophageal circumference
Clinical Characteristics of Elderly GERD Patients 101respond to PPI twice daily with those who responded to PPI at least
once daily.
2. Materials and methods
2.1. Patients
GERD patients who had received PPI (omeprazole/esomepra-
zole 20 mg, lansoprazole 30 mg, rabeprazole 10 mg, or pan-
toprazole 40 mg) once or twice daily for at least 3 months were
enrolled in this study. Prior to PPI treatment, patients reported at
least three incidences of heartburn or acid regurgitation per
week.
Patients were then categorized into two groups: those who
responded to PPI once and/or twice daily (Group R) and those
who failed to respond to PPI twice daily (Group F). Group R pa-
tients reported that their heartburn and acid regurgitation
symptoms were relieved, the EE was downgraded by one or more
level regardless of symptoms, or the time of pathological acid
reﬂux was decreased by 30% regardless of symptoms after
receiving PPI treatment once or twice a day for the past
3 months. However, Group F patients continued to suffer from
heartburn and acid regurgitation at least three times a week for
the past 3 months, the EE was unimproved or exacerbated
regardless of symptoms, or the time of pathological acid reﬂux
was decreased by <30% regardless of symptoms despite receiving
PPI twice daily.
All patients' clinical data including their demographics, comor-
bidities, medications, symptoms, compliance with treatment (if
patients took the PPI daily), and adherence to treatment (if patients
took the PPI before a meal) were collected via a questionnaire, and
their endoscopic ﬁndings were also recorded.
2.1.1. Inclusion criteria
Patients who were older than 65 years and had typical symp-
toms of heartburn and acid regurgitation, or were deﬁnitely diag-
nosed with EE by endoscopy or nonerosive reﬂux disease by 24-
hour gastroesophageal pH monitoring test despite typical symp-
toms were included.
2.1.2. Exclusion criteria
Patients who had a history of gastric or esophageal surgery or
peptic ulcer, and were unable to fulﬁll the questionnaire or provide
the information requested by the protocol were excluded.
This study was approved by the medical ethics committee of the
Chinese PLA General Hospital, Beijing, China.
2.2. Procedure
Patients meeting the inclusion criteriawere requested to ﬁll up a
questionnaire with data regarding their demographics, comorbid-
ities, medications, and symptoms related to GERD, and were
interviewed about their compliance with treatment (if patients
took the PPI daily) and adherence to treatment (if patients took the
PPI before a meal).
2.3. Demographics
All patients enrolled in this study completed a questionnaire
with information regarding age, sex, weight, height, body mass
index (BMI), family status (single, married, divorced, or widowed),
and current smoking and alcohol-drinking status. BMI was calcu-
lated using each individual's weight and height. The patients'
comorbidities, such as hypertension, diabetes mellitus, chronic
obstructive pulmonary disease, ischemic heart disease, renalfailure, depression, Helicobacter pylori infection, and asthma, were
also recorded, together with their medications.
2.4. Evaluation of GERD-related symptoms
Patients' atypical reﬂux symptoms, such as chest pain, epigastric
pain, cough, sleep disturbance, abdominal distension, and
dysphagia were recorded.
2.5. Compliance with and adherence to therapy
Patients were interviewed whether they took PPI according to
the prescribed dose in the past 3 months. Compliance was assessed
by asking the patients whether they kept taking the PPI at the
prescribed dose during the past 3 months. Adherence was evalu-
ated by conﬁrming whether the patients took the PPI half an hour
before a meal or not. Patients who took the PPI with or after a meal
were considered to be nonadherent, while those who did not take
PPI at the prescribed dose were considered to be noncompliant.
2.6. Endoscopic ﬁndings
Patients' upper endoscopic ﬁndings were needed to evaluate the
degree of esophageal mucosal breaks and the presence of hiatal her-
nia. The degree of esophageal mucosal breaks was categorized ac-
cording to theLosAngeles classiﬁcation,which ispresented inTable1.
2.7. Statistical methods
SPSS 20.0 statistical analysis software (IBM SPSS Statistics,
Armonk, New York, United States) was used for data analysis.
Continuous variables, such as age, weight, and height, were re-
ported as mean ± standard deviation. Normality of distribution of
continuous variables was assessed using the KolmogoroveSmirnov
test (cutoff at p ¼ 0.05). Continuous variables were compared be-
tween groups using independent-samples t test. Categorical vari-
ables were expressed in frequency (%). The comparison of
categorical variables between groups used the chi-square test.
Multiple logistic regression was used to model variables. Odds ra-
tios were estimated with 95% conﬁdence intervals. All tests were
two sided and considered signiﬁcant at p < 0.05.
3. Results
3.1. Demographics
A total of 261 patients with GERD were recruited, while 63 pa-
tients were lost to follow up. Ultimately, a total of 198 patients
meeting the inclusion criteria were included in the study; of them,
135 fully responded to PPI once or twice daily (Group R) and 63
failed to respond to PPI twice daily (Group F).
Patients' characteristics are listed in Table 2. Themean age of the
patients was 75.9 ± 6.4 years and male patients accounted for
Table 2
Comparison of clinical characteristics between groups.
Characteristics Group R (n ¼ 135) Group F (n ¼ 63) p
Age (y) 76.03 ± 6.27 75.62 ± 6.56 0.673
Sex (male, %) 75.6 69.8 0.395
Weight (kg) 74.89 ± 9.66 76.27 ± 8.27 0.329
Height (cm) 170.85 ± 7.95 169.6 ± 8.98 0.324
BMI 25.76 ± 2.32 26.5 ± 2.49 0.042
Present smoker 11 (8.1) 9 (14.3) 0.182
Present drinker 25 (18.5) 13 (20.6) 0.725
Family status 0.028
Married 91 (67.4) 30 (47.6) 0.008
Divorced 6 (4.4) 5 (7.9) 0.505
Widowed 38 (28.1) 28 (44.4) 0.023
Data are presented as mean ± SD or n (%).
BMI ¼ body mass index; SD ¼ standard deviation.
Table 4
Comparison of atypical GERD symptoms between groups.
Group R (n ¼ 135) Group F (n ¼ 63) p
Symptoms
Cough 18 (13.3) 17 (27) 0.019
Dysphagia 8 (5.9) 6 (9.5) 0.358
Chest pain 28 (20.7) 15 (23.8) 0.626
Epigastric pain 34 (25.2) 22 (34.9) 0.157
Sleep disturbance 46 (34.1) 31 (49.2) 0.042
Abdominal distension 19 (14.1) 12 (19) 0.370
Data are presented as n (%).
GERD ¼ gastroesophageal reﬂux disease.
Y.-N. Li et al.10273.7%. There was no signiﬁcant difference between Groups R and F,
in terms of smoking and drinking habits. However, a signiﬁcantly
higher BMI was observed for patients in Group F compared with
that in Group R. Furthermore, statistically signiﬁcant differencewas
also detected in family status of patients between the two groups:
there were a higher proportion of married patients and a lower
proportion of widowed patients in Group R than in Group F.
3.2. Comorbidities and medications
Patient comorbidities of the two groups are shown in Table 3.
The proportion of patients with diabetes mellitus in Group F was
higher than that in Group R. A higher proportion of patients with
depression was also observed in Group F. However, no signiﬁcant
difference was observed in patients with hypertension, chronic
obstructive pulmonary disease, ischemic heart disease, renal fail-
ure, H. pylori infection, and asthma between the two groups. In
terms of medications, more patients took calcium channel blockers
(CCBs) and benzodiazepines in Group F than those in Group R, but
there was no evident difference in the number of patients taking
nitrates, aspirin, and clopidogrel between the two groups.
3.3. Atypical GERD symptoms
Atypical GERD symptoms are listed in Table 4. A number of
symptoms differed signiﬁcantly between the two groups. The
proportions of patients with symptoms of cough and sleep distur-
bance were signiﬁcantly higher in Group F than in Group RTable 3
Comparison of comorbidities and medications between groups.
Comorbidities and medications Group R
(n ¼ 135)
Group F
(n ¼ 63)
p
Comorbidities
Hypertension 71 (52.6) 40 (63.5) 0.150
Diabetes mellitus 15 (11.1) 19 (30.2) 0.001
COPD 68 (50.4) 33 (52.4) 0.792
Ischemic heart disease 52 (38.5) 27 (42.9) 0.561
Renal failure 7 (5.2) 5 (7.9) 0.663
Depression 1 (0.7) 5 (7.9) 0.030
Helicobacter pylori infection 47 (34.8) 24 (38.1) 0.654
Asthma 11 (8.1) 9 (14.3) 0.182
Medications
Calcium channel blockers 55 (40.7) 37 (58.7) 0.018
Nitrates 45 (33.3) 25 (39.7) 0.384
Benzodiazepines 52 (38.5) 37 (58.7) 0.008
Aspirin 58 (43) 28 (44.4) 0.845
Clopidogrel 18 (13.3) 11 (17.5) 0.444
Data are presented as n (%).
COPD ¼ chronic obstructive pulmonary disease.(p¼ 0.019 and p¼ 0.042, respectively). For other symptoms, such as
dysphagia, chest pain, epigastric pain, and abdominal distension,
no signiﬁcant difference was observed between the two groups.
3.4. Adherence to and compliance with treatment
The proportions of compliant patients in Groups R and F were
77% and 60%, respectively, which were statistically signiﬁcant
(p ¼ 0.015).
3.5. Endoscopic ﬁndings
Endoscopic ﬁndings are presented in Table 5. The morbidity of
hiatal hernia was signiﬁcantly lower in Group R than in Group F
(p ¼ 0.019).
There were no patients with EE Grade D (Los Angeles grade) in
both groups. Although no signiﬁcant difference was observed in
patients with EE Grades A and B between the two groups (p¼ 0.541
and p ¼ 0.251, respectively), there were fewer patients with EE
Grade C in Group F (p ¼ 0.021).
3.6. Multiple logistic regression analysis
As shown in Table 6, BMI, hiatal hernia, and depression signiﬁ-
cantly increased the odds of being a PPI nonresponder, while
compliance with treatment showed the opposite trend. Family
status was another signiﬁcant risk factor for nonresponse to PPI
therapy: married patients were less likely to be nonresponders
compared with those who were widowed. However, hypertension,
diabetes mellitus, CCBs, benzodiazepines, sleep disturbance, and
Los Angeles grade of EE were not signiﬁcant risk factors.
4. Discussion
According to the Montreal deﬁnition, GERD is deﬁned as the
presence of acid-reﬂux-related symptoms, or esophageal mucosal
damage, caused by the abnormal reﬂux of gastric contents into the
esophagus1. Previous studies have shown that multiple factors
contribute to the development of GERD. In elderly patients, GERD
becomesmore common and severe. Elderly patients tended to have
more risk of acid-related disorder due to havingmore comorbiditiesTable 5
Endoscopic ﬁndings.
Endoscopic ﬁndings Group R (n ¼ 135) Group F (n ¼ 63) p
Los Angeles grade of EE 0.015
Grade A 23 (17) 13 (20.6) 0.541
Grade B 12 (8.9) 9 (14.3) 0.251
Grade C 1 (0.7) 5 (7.9) 0.021
Hiatal hernia 9 (6.7) 11 (17.5) 0.019
Data are presented as n (%).
EE ¼ erosive esophagitis.
Table 6
Odds ratios for PPI failure of patients by multiple logistic regression analysis.
Characteristics OR 95% CI p
BMI 1.345 0.530e0.715 0.036
Family status 0.707 0.506e0.987 0.042
Compliance with treatment 0.636 0.333e0.917 0.020
Diabetes mellitus 0.871 0.321e2.619 0.871
Depression 2.046 12.812e29.683 0.035
Calcium channel blockers 0.763 0.382e1.523 0.443
Benzodiazepines 0.704 0.356e1.392 0.313
Cough 1.392 0.724e2.673 0.321
Sleep disturbance 1.135 0.578e2.229 0.713
LA grade of EE 0.943 0.800e1.112 0.484
Hiatal hernia 2.196 0.760e0.945 0.016
BMI¼ bodymass index; CI¼ conﬁdence interval; EE¼ erosive esophagitis; LA¼ Los
Angeles; OR ¼ odds ratio; PPI ¼ proton pump inhibitor.
Clinical Characteristics of Elderly GERD Patients 103and taking medications such as nonsteroidal anti-inﬂammatory
drugs, etc8. Our study presents a comprehensive evaluation of the
clinical characteristics of elderly GERD patients who respond to or
are refractory to PPI therapy.
Our study showed that poor compliance with treatment is the
most important reason for PPI treatment failure among GERD
patients. According to a large population-based survey, only 55%
of the GERD patients took their PPIs as prescribed. In contrast, 37%
took their PPI only for 12 d/mo9. For elderly patients, it is more
common to take medicine irregularly. Since GERD is primarily a
symptom-driven disease, many patients continue to take medi-
cations as long as they experience symptoms, but tend to forget to
take PPI when symptoms are resolved, leading to discontinuation
of treatment10.
Over decades, ample evidence has accumulated that psycho-
logical factors are associated with gastrointestinal diseases11. Our
study clearly demonstrated that depression is associated with un-
satisfactory PPI treatment to GERD patients. In our study, ﬁve of six
patients with depression failed to respond to PPI therapy, which
indicated that psychological state and stress played important roles
in the treatment of GERD patients. Does psychological distress
result in symptomatology or do symptoms result in psychological
distress? Psychological state has an impact on perception, rather
than on causal mechanisms. Patients could become hypervigilant,
resulting in perception of symptoms. Exacerbation and increased
symptom perception might cause more elevated levels of psycho-
logical distress. Thus, a vicious circle in which these two pathways
reinforce each other can be envisioned11.
In this study, we also found that obese patients are more likely
to be refractory to PPI therapy. Several studies have shown that
obese patients experience more esophageal acid exposure than
nonobese patients12e14. A mechanically defective lower esophageal
sphincter was shown to be more frequent in patients with a higher
BMI, and obese patients were more than two times more likely to
have a defective lower esophageal sphincter compared with pa-
tients of normal weight13. Moreover, obesity may also alter the
pharmacokinetics of acid-suppressive therapies, including distri-
bution (e.g., poor blood ﬂow in adipose tissue, obesity-related
changes in plasma concentrations of binding proteins, and varia-
tions in lipophilicity of drugs), metabolism (e.g., fatty liver disease,
common in obese patients, slowing the enzymatic metabolism of
drugs), and elimination (e.g., increased glomerular ﬁltration rates
and tubular secretion, associated with obesity, accelerating the
elimination of some drugs)15e17.
In addition, we observed that hiatal hernia was another
important reason for PPI failure in elderly GERD patients. The
presence of a hiatal hernia impairs the function of the lower
esophageal sphincter and may also impair the clearance of reﬂuxedacid from the distal esophagus18. The prevalence of hiatal hernia
appears to increase with age19. Indeed, a large percentage of elderly
patients with reﬂux esophagitis have hiatus hernia.
Another important observation of our studywas the inﬂuence of
the family status. In this study, patients who were divorced or
widowed were more likely to be refractory to PPI therapy. A plau-
sible explanation is that elderly patients who are divorced or
widowed usually live on their own and suffer from a lack of care
from children or friends. Due to their insufﬁcient self-care capa-
bility and memory loss, these patients tend to have a life of poor
quality and do not always comply with PPI therapy. Moreover,
psychological problems caused by loneliness, such as depression,
dread, pessimism, etc., would also contribute to the PPI failure.
Therefore, it is important to paymore attention to the psychological
well-being as well as medication of elderly GERD patients.
Adverse effects of drugs on the esophagus should also be taken
into consideration. Many widely used medications, such as nitro-
glycerins, anticholinergics, b-adrenergic agonists, aminophyllines,
benzodiazepines, and CCBs can induce lower esophageal sphincter
relaxation20. The effect of benzodiazepines on lower esophageal
sphincter had been reported by Rushnak and Leevy21 in 1980.
Similarly, CCBs have been proved to be associated with impaired
esophageal motility and increase of esophageal exposure to gastric
acid. Our study showed that more patients took CCBs and benzo-
diazepines in Group F than in Group R. PPIs might be less effective
or not effective at all when combined with treatment using the
drugs listed above. Therefore, elderly GERD patients need to be
made aware of the interactions between PPIs and these drugs.
Several problems still exist in our study: The samples in this
study was not so abundant as we expect that we did not divide the
groups of responders into two groups (fully responders and partly
responders). Furthermore, the effect of PPI therapy was evaluated
by subjective symptoms and not by objective indicators such as
GERD questionnaire scores. If these issues were taken care of, the
results of this study would have been more convincing.5. Conclusion
Our study provides a comprehensive evaluation of the clinical
characteristics of elderly GERD patients who are refractory to PPI
therapy. We found that PPI failure appeared to be signiﬁcantly
associated with the patients' BMI, family status, compliance with
treatment, depression, and hernia. These clinical ﬁndings are very
valuable for an effective management of patients with GERD re-
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